C
CK Regeon
Wnt/β-catenin pathway drugs for regenerative medicine applications
About CK Regeon
CK Regeon Inc. is a South Korean biotechnology firm established in October 2016 by Professor Kang-Yell Choi of Yonsei University. The company spun out from the Transnational Research Center for Protein Function Control (TRCP), a government-funded drug development institute that Dr. Choi had directed for over a decade. Dr. Choi, who holds a Ph.D. in biochemistry from Purdue University and conducted postdoctoral research at Harvard Medical School, founded CK Regeon to commercialize his extensive research on cellular signaling pathways, particularly the Wnt/β-catenin pathway.
The company's core focus is the development of First-in-Class, small-molecule drugs that address unmet medical needs by targeting the Wnt/β-catenin signaling pathway, which is crucial for tissue regeneration. A key discovery underpinning their technology is the role of the CXXC-type zinc finger protein 5 (CXXC5). CK Regeon identified that CXXC5 acts as a negative feedback regulator that suppresses the Wnt/β-catenin pathway by binding to the Dishevelled (Dvl) protein, and that this protein is overexpressed in damaged or diseased tissues. By developing drugs that inhibit this CXXC5-Dvl interaction, the company aims to restore the natural regenerative capabilities of tissues.
CK Regeon's therapeutic pipeline targets a range of conditions characterized by suppressed Wnt signaling. One of its leading drug candidates is KY19382, an oral small molecule that dually inhibits both the CXXC5-Dvl interaction and GSK3β to activate the Wnt pathway. This candidate has shown potential in preclinical studies for treating metabolic diseases like obesity and non-alcoholic steatohepatitis (NASH), demonstrating significant weight loss in high-fat diet animal models. The company is also developing topical applications of its technology to promote hair regrowth and accelerate wound healing. The compound KY19382 has demonstrated the ability to induce hair follicle neogenesis (the formation of new hair follicles) and accelerate cutaneous wound closure in animal studies. In July 2025, the company announced the launch of a cosmetic line under the brand names 'Herabone' and 'Hair Region', which includes shampoos and microneedle products for scalp health, marking a step towards commercialization.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2021 | $11M | $45M | Synergy IB Investment | ↗ |
| SERIES A✓Equity / VC | Jan 2018 | $5M | $20M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for CK Regeon is 2.1K monthly website visits, down 71.6% over the last three months. CK Regeon's team declined 16.7% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CK Regeon in its local ecosystem
The CK Regeon office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Synergy IB Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CK Regeon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CK Regeon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.